EPGL Discussion 08/25/2014 05:24:06 $EPGL
EPGL summed that up best on July 18th, 2014 when they updated shareholders.
Quote:
It can now be revealed that both Novartis and Google reached out to our development team members in recent weeks and months. This fact should be a clue to the gravity and know-how of our team in both BioMEMS and manufacturing of smart contact lenses. We intend to set the industry's standard with our enabling technology. Who are we teamed up with? Who will ultimately include EPGL originated technology.
Doesn't Google want to do this???!!! Or some other behemoth? I read somewhere that Google was trying to make a smart contact lens.
They all want to, but none of them, other than EPGL, has the technology to make it all work. It's still very 'new'. But Dr. Markus has been working on it for the past 2+ decades. Google made a big deal a few months ago about how they were developing a smart contact lens. However, to their dismay, they failed at being able to make it work and have reached out to EPGL for help, as well as contact lens giant, Novartis.
EPGL Stock Message Board http://investorshangout.com/EP-Global-Communi...PGL-87206/
Due to a non-disclosure agreement (NDA) between the company and EPGL, which is a common business practice with these types of deals, EPGL is currently unable to divulge who the company is or the terms of the deal. But the information is going to be released soon.
Since then investors have been speculating on who the company is and what impact it will have on EPGL.
Then EPGL announced the following"
Quote:
EPGL Announced Advanced Contact Lens Technology in August of 2013. Since then our technology and know how has caught the eyes of the world's leading companies in the field. Now, EPGL is on the forefront of innovating the technology and EPGL MEMS will be inside the world's most advanced contact lenses as we move into this new revolution of smart, wearable technology.
EPGL technologies are on the cutting edge and in demand. We believe current dedicated shareholders will be proven to be "visionary".
That pretty much summed up that they are working on a smart contact lens. Then they soon followed up that announcement with:
Quote:
EPGL is leading the advance MEMS technology design and product development for one of the largest companies in its field. The relationship has expanded under phase two and involves co -ownership of product technologies under development. All EPGL technologies are involved. The technology and products will be manufactured by the NYSE company branded under its name and distributed worldwide, by that Company and others affiliated. EPGL's role is that of research, design, development and ownership of the various technology applications. We are developing an "open source" platform with this company to enable many other organizations and entities to create new products with a new platform. EPGL shareholders should realize that this situation is very real and developing. We are getting very much closer to the time we can reveal all. This will happen no later than August 29, 2014.
EPGL is unlike any other OTC Pink Sheet company at this time. Shareholders are right to be excited about our future. By the way,EPGL and our partners could make an announcement sooner that August 29, 2014.
December of 2013, they were selected by a multi-billion dollar NYSE company to integrate EPGL's tech into theirs.
December 16th, 2013
EPGL Technology Selected by Major Corporation for Development
In a first for the company, one of EPGL's advanced technologies has been selected by a multi-billion dollar, NYSE publicly traded industry leader for development and integration into new products. "This is the biggest development for our company in its history," said David T. Markus PhD.”
EPGL Technology Selected by Major Corporation for Development
June 18th, 2013
EPGL Medical Unveils New Devices and Intellectual Property Under EP Global Communications, Inc. Ownership
Advanced Device Prototypes on the Way Along with FDA 510k and PMA Applications.
New Devices and Intellectual Property
1. A new advanced ablation device for nerve pain treatment in the back.
2. A new advanced ablation device for nerve treatment of Facial Glabballar Frowning.
3. A new advanced device for elimination of facial wrinkles.
4. A new advanced Epidural device.
5. A new advanced power source for TopSpin medical devices.
6. A new and promising device for treatment of Retinitis Pigmentosa
7. A new and promising device for treatment of Macular Degeneration
8. A new and promising treatment for Hearing Loss
9. A new more accurate treatment for trigger points in the muscles (MPTT)
10. A new advanced device for treatment of prostate tumors.
11. A new advanced endoscopic device.
12. A new advanced device for delivery of micron sized drug payloads.
13. A new advanced device for delivery of micro mechanical devices into the body.
14. A new advanced device for biopsy.
15. A new advanced device for stem cell treatment delivery.
16. A new advanced contact lens device.
Feel free to check out these articles based upon Dr. Markus and EPGL's technology.
Will EPGL's TopSpin Serve Up the Next Generation of Medical Devices?
Company Designs MEMS-Based Energy Harvester for Contact Lenses
EPGL: .10 will be on the bid today. Small float and majority shares are restricted. Hard to get in again when some people sold early.
I believe new MM's join the party shortly after EPGL closes .10+, this will add more liquidity. Also believe funds have started buying into EPGL already.
EPGL seeing new MM's starting to buy shares
EPGL Seeing increased liquidity $1,000,000 money flow last week
About David T. Markus, Ph.D. Vice President - BioMems Development
David T. Markus holds a Ph.D. in Biomedical Engineering and a MS in Electrical Engineering with an emphasis in MEMS Microelectronics and Biomedical. Dr. Markus spent 11 years with Raytheon and holds 8 US patents and has 9 other US Patents Pending. He has been involved in research for several of the world's leading technological institutions, including the Office of Naval Research in Arlington, Virginia, NASA Jet Propulsion Laboratory in Pasadena, CA and he has been published 15 times for various technical conferences. He was a principal investigator on SBIR DARPA Phase I and Phase II, and "Ultraflexible Substrate" for Macroelectronics Program by Dr. Robert Reuss at DARPA. He has been involved in the engineering and the development on seven surgical devices, including devices for Cataract surgery, Intra-Ocular Lens Delivery, Arthroscopy, Endodontic Endoscope, Micro Endoscope and Neural Electrodes. Additionally he was instrumental on developing three medical laboratory devices, including for In-Vitro Fertilization, PCR instrumentation and drug discovery. Finally, Dr. Markus is fluent in English, Chinese-Madarin, Taiwanese-FuJian and Indonesian languages.
$$$$$ EPGL $$$$$
$EPGL
#MEMS
MD+DI Article-> Nice article on EPGL from a leading industry source.
Will EPGL's TopSpin Serve Up the Next Generation of Medical Devices?
A former DARPA scientist and a device startup want to change medical devices forever using bioMEMS
A phone call with EPGL Medical Science is not unlike a game of Texas hold 'em, you don't know exactly what the guys across the table are holding, but you definitely know you should at least be paying attention. MD+DI profiled EPGL last month when the company announced it would be among the first medical device companies to implement Google Glass technology. But company president and CEO Michael Hayes was more excited about something else going on at EPGL – a bioMEMS platform, codenamed TopSpin, that EPGL says will usher in nothing short of a paradigm shift for medical devices and the doctors and patients that use them. The goal is to do for medical devices what Steve Jobs did for phones.
The ace in the hole is Dr. David T. Markus, the company's VP of bioMEMS development. Markus comes to the company with an extensive background in MEMS, microelectronics, and biomedical engineering. He was also a principal investigator at DARPA, where the forefront of MEMS research has been conducted for years. “They brought together the best scientists in America, essentially doing research that is so advanced, it has little practical use, but not in all cases” Markus laughs. “As a result of being part of those programs and others, some new advanced technology was developed and I just so happened to be involved in the development of some of those technologies. As a result I was able to know how to replicate them for practical use in the medical field.”
Dr. David Markus wants to serve up the world's most advanced medical devices
Markus, who is fluent in seven languages, speaks with an ease that belies just how large of an impact he's attempting to have on the medical device industry. And if Hayes' boast that EPGL is “Three to five years ahead of any device company in this field because of David Markus,” is true, perhaps he should. He and Hayes met as friends on the tennis court and later bonded when Hayes began speaking with him about ideas for new and improved medical devices. “I had all of these ideas and hadn't realized I was contemplating MEMS ideas,” Hayes says. “David has given me quite an education on what the possibilities are with MEMS. Based on that I've made a decision that EPGL is going to be a company focused largely on advanced MEMS devices.”
MEMS technology has already impacted a variety of fields from robotics, to personal fitness, and even digital movie projection. Markus and the team at EPGL figure it is medtech's turn. “The reason why we're very confident is because this isn't dreamland stuff, this is technology that exists right now,” Hayes says. “Everything David is working on is technology that he knows how to implement.”
So what is TopSpin exactly? Or, more accurately, what does it hope to become? Imagine all of the devices doctors now use in the hospital and clinical setting for a wide variety of procedures. Some of these devices and machines are large and require designated rooms in the clinic or hospital for use. Now imagine many of those devices sharing the same core platform with advanced MEMS technology, making them much smaller, less invasive and more effective and you have the beginnings of what TopSpin promises. While Markus and his team are sworn to secrecy for full details, he does promise “Topspin will be small and noninvasive. It will be packed with all necessary smart systems. It can achieve 1 micron in movement. And it is an intelligent microsystem with advanced technology that no Fortune 500 company owns.”
A sample of bioMEMS technology for drug delivery previously developled by Dr.Markus
Markus wants clinicians to feel the same impact with TopSpin that consumers did with the touchscreen not too long ago. “It was shocking when the iPhone finally came to market. People said, 'Wow I didn't know a touchscreen could be this dynamic' “ Markus says. “ I'm sure you remember before the iPhone that the touchscreen experience was only as good as a PDA with stylus. But look at something like Gorilla Glass. It was developed by Corning in 1960 but was put on a shelf. Nobody knew it existed until Apple started using it in the iPhone.” While he remains close-lipped about much of his DARPA background Markus, very modestly, states that “You'd be amazed how much technology is out there and is available in the world.”
Hayes likes to extend the iPhone analogy when talking about TopSpin. Just as the iPhone is more than a phone and functions as a platform for application development (ala the AliveCor heart monitor), so too will TopSpin be a platform for medical device applications. The key distinction is that EPGL doesn't want to create Star Trek-style TriCorder. “We're not saying you'll hold one single device in your hand and it'll do everything,” Hayes says. “ We've developed a platform by which many different MEMS devices can be spawned, but it's all based on two or three components to the main device. But literally dozens and dozens of new devices can result from this one single device. It'll result in several unique patented devices.” As of late Markus and his team are already boasting 10, as yet to be revealed, pain management devices that have been created with the platform. Hayes predicts that anywhere up to five of these devices should be in the prototype phase and undergoing FDA 510(k) applications by fourth quarter 2013.
“The gist of it is is that we're taking bioMEMS technology, utilizing nature and the senses we have as living creatures such as touch, taste, sight, sound, balance, and giving these senses to devices. It's the ability for devices to almost become superhuman,” Hayes says.
“Take a doctor who would never consider doing a certain procedure now because they don't have the facilities or they would normally have to perform the procedure in a hospital or O.R. setting. What we're offering is several devices that will give physicians who don't have the current ability to do certain procedures the ability to do these procedures in a clinical setting in a compact and effective way,” Hayes continues.
If EPGL's ambitions ring true one won't be able to deny the inherent cool factor of the TopSpin. But Markus is quick to emphasize that this is not invention or innovation for the sake of doing so. There's a real goal in helping doctors in speeding up patient recovery and, ultimately, in reducing medical costs. “The device will be produced based on doctors' feedback when treating patients,” he says. “It's not based on any engineer notions of what's good for the doctor. We asked doctors what they needed.”
A paradigm shift? Game changer? Both Hayes and Markus acknowledge how lofty their words must sound, especially without a finished device yet revealed to the public. But Hayes carries himself like a player who knows he has a winning hand, he just needs to wait his turn. “I realize the Fortune 500 companies like Medtronic or St. Jude will look at us and scoff like we're another newcomer trying to thump their chest,” Hayes says. “And to some extent they're right because we're a pittance compared to them currently financially. But we have technology that we know they would love to have and that's what makes us something meaningful and something to recon with in the future.”
Confidence certainly, but as any experienced player will tell you only time will tell whether EPGL is holding the winning cards or have merely mastered the art of the bluff. Still, one gets the sense that Hayes has no trouble looking you in the eye when he says, “We're trying to usher in the era of the smart medical device- smarter medical devices... the smartest medical devices.”
-Chris Wiltz, Associate Editor, MD+DI
$EPGL
#MEMS
#DAVIDMARKUS
New Devices and Intellectual Property Under EPGL Ownership
1.A new advanced ablation device for nerve pain treatment in the back.
2. A new advanced ablation device for nerve treatment of Facial Glabballar Frowning.
3. A new advanced device for elimination of facial wrinkles.
4. A new advanced Epidural device.
5. A new advanced power source for TopSpin medical devices.
6. A new and promising device for treatment of Retinitis Pigmentosa
7. A new and promising device for treatment of Macular Degeneration
8. A new and promising treatment for Hearing Loss
9. A new more accurate treatment for trigger points in the muscles (MPTT)
10. A new advanced device for treatment of prostate tumors.
11. A new advanced endoscopic device.
12. A new advanced device for delivery of micron sized drug payloads.
13. A new advanced device for delivery of micro mechanical devices into the body.
14. A new advanced device for biopsy.
15. A new advanced device for stem cell treatment delivery.
16. A new advanced contact lens device.
$EPGL
#MEMS
#DAVIDMARKUS
Reposting information for the newbies to EPGL, I also suggest they look at the stickies above, a lot of NEW people looking at EPGL, another few days we will have much more new information to go though and digest when filings and or news hit
Over the last few days I have had more people asking me about EPGL through many sources,(NOT JUST HERE), then I probably have over the last 3 months combined, EPGL is hitting many new radars...
I direct them to the DD provided and encourage them to follow EPGL on twitter as well as check out EPGL website.
Recent EPGL Twitter Updates--> 6/19,7/17,7/18,7/23, BELOW
EPGL Twitter Update 6/19/2014 ->
EPGL is leading the advance MEMS technology design and product development for one of the largest companies in its field. A NYSE
The relationship has expanded under phase two and involves co -ownership of product technologies under development. All EPGL technologies are involved. The technology and products will be manufactured by the NYSE company branded under its name and distributed worldwide by that Company and others affiliated. EPGL's role is that of research, design, development and ownership of the various technology applications.
We are developing an "open source" platform with this company to enable many other organizations and entities to create new products with a new platform. EPGL shareholders should realize that this situation is very real and developing. We are getting very much closer to the time we can reveal all. This will happen no later than August 29, 2014.
EPGL is unlike any other OTC Pink Sheet company at this time. Shareholders are right to be excited about our future. By the way, EPGL and our partners could make an announcement sooner that August 29, 2014.
From EPGL management and team, have a wonderful day.
EPGL Twitter Update 7/17/2014
Google took glucose lens as far as they could. Now the "X" man is an ex-man. Enter Novartis to try to figure it out. But Novartis reached out to EPGL not long ago. So whose technology will dominate coming smart lens revolution?
EPGL is leading giants and focused on new smart lens technologies which will enable mass marketing in both health and consumer electronics well into the future.
Many companies and institutions stand to be enabled by our work. EPGL is working with the best in the business and more is to come by August 29, 2014. EPGL shareholders should be excited at the prospects. Have a wonderful weekend from EPGL team.
TWITTER UPDATE 7/18/2014
It can now be revealed that both Novartis and Google reached out to our development team members in recent weeks and months.
This fact should be a clue to the gravity and know-how of our team in both BioMEMS and manufacturing of smart contact lenses.
We intend to set the industry's standard with our enabling technology. Who are we teamed up with? Who will ultimately include EPGL originated technology within their coming smart lenses? August 29th or before, we intend to go into more details as we've previously announced.
TWITTER UPDATES 7/23/2014
Here's an example of the caliber of suitors. Who did we choose to team our technology with? 1/2
The best in the business. Find out soon... 2/2
Read More: http://investorshangout.com/post/view?id=1733...z3BNTCc4vl
Follow EPGL on twitter @EPGLMed
https://twitter.com/EPGLMed
EPGL Weekly Chart ->Major accumulation
EPGL Daily Chart ->
Here is my last response on this issue, because this is what matters.
Who has the sole power to manage the EPGL shares for AJW? Who is the only organization that can buy or sell EPGL shares? By the way, Mr. Hayes has first right of refusal on any sell.
EOM
$$$$$ EPGL $$$$$$
If you're appointed as power of attorney for a piece of property essentially you own it.
EPGL summed that up best on July 18th, 2014 when they updated shareholders.
Quote:
It can now be revealed that both Novartis and Google reached out to our development team members in recent weeks and months. This fact should be a clue to the gravity and know-how of our team in both BioMEMS and manufacturing of smart contact lenses. We intend to set the industry's standard with our enabling technology. Who are we teamed up with? Who will ultimately include EPGL originated technology.
Doesn't Google want to do this???!!! Or some other behemoth? I read somewhere that Google was trying to make a smart contact lens.
They all want to, but none of them, other than EPGL, has the technology to make it all work. It's still very 'new'. But Dr. Markus has been working on it for the past 2+ decades. Google made a big deal a few months ago about how they were developing a smart contact lens. However, to their dismay, they failed at being able to make it work and have reached out to EPGL for help, as well as contact lens giant, Novartis.
EPGL Stock Message Board http://investorshangout.com/EP-Global-Communi...PGL-87206/
Due to a non-disclosure agreement (NDA) between the company and EPGL, which is a common business practice with these types of deals, EPGL is currently unable to divulge who the company is or the terms of the deal. But the information is going to be released soon.
Since then investors have been speculating on who the company is and what impact it will have on EPGL.
Then EPGL announced the following"
Quote:
EPGL Announced Advanced Contact Lens Technology in August of 2013. Since then our technology and know how has caught the eyes of the world's leading companies in the field. Now, EPGL is on the forefront of innovating the technology and EPGL MEMS will be inside the world's most advanced contact lenses as we move into this new revolution of smart, wearable technology.
EPGL technologies are on the cutting edge and in demand. We believe current dedicated shareholders will be proven to be "visionary".
That pretty much summed up that they are working on a smart contact lens. Then they soon followed up that announcement with:
Quote:
EPGL is leading the advance MEMS technology design and product development for one of the largest companies in its field. The relationship has expanded under phase two and involves co -ownership of product technologies under development. All EPGL technologies are involved. The technology and products will be manufactured by the NYSE company branded under its name and distributed worldwide, by that Company and others affiliated. EPGL's role is that of research, design, development and ownership of the various technology applications. We are developing an "open source" platform with this company to enable many other organizations and entities to create new products with a new platform. EPGL shareholders should realize that this situation is very real and developing. We are getting very much closer to the time we can reveal all. This will happen no later than August 29, 2014.
EPGL is unlike any other OTC Pink Sheet company at this time. Shareholders are right to be excited about our future. By the way,EPGL and our partners could make an announcement sooner that August 29, 2014.
December of 2013, they were selected by a multi-billion dollar NYSE company to integrate EPGL's tech into theirs.
December 16th, 2013
EPGL Technology Selected by Major Corporation for Development
In a first for the company, one of EPGL's advanced technologies has been selected by a multi-billion dollar, NYSE publicly traded industry leader for development and integration into new products. "This is the biggest development for our company in its history," said David T. Markus PhD.”
EPGL Technology Selected by Major Corporation for Development
June 18th, 2013
EPGL Medical Unveils New Devices and Intellectual Property Under EP Global Communications, Inc. Ownership
Advanced Device Prototypes on the Way Along with FDA 510k and PMA Applications.
New Devices and Intellectual Property
1. A new advanced ablation device for nerve pain treatment in the back.
2. A new advanced ablation device for nerve treatment of Facial Glabballar Frowning.
3. A new advanced device for elimination of facial wrinkles.
4. A new advanced Epidural device.
5. A new advanced power source for TopSpin medical devices.
6. A new and promising device for treatment of Retinitis Pigmentosa
7. A new and promising device for treatment of Macular Degeneration
8. A new and promising treatment for Hearing Loss
9. A new more accurate treatment for trigger points in the muscles (MPTT)
10. A new advanced device for treatment of prostate tumors.
11. A new advanced endoscopic device.
12. A new advanced device for delivery of micron sized drug payloads.
13. A new advanced device for delivery of micro mechanical devices into the body.
14. A new advanced device for biopsy.
15. A new advanced device for stem cell treatment delivery.
16. A new advanced contact lens device.
Feel free to check out these articles based upon Dr. Markus and EPGL's technology.
Will EPGL's TopSpin Serve Up the Next Generation of Medical Devices?
Company Designs MEMS-Based Energy Harvester for Contact Lenses
EPGL: .10 will be on the bid today. Small float and majority shares are restricted. Hard to get in again when some people sold early.
I believe new MM's join the party shortly after EPGL closes .10+, this will add more liquidity. Also believe funds have started buying into EPGL already.
EPGL seeing new MM's starting to buy shares
EPGL Seeing increased liquidity $1,000,000 money flow last week
About David T. Markus, Ph.D. Vice President - BioMems Development
David T. Markus holds a Ph.D. in Biomedical Engineering and a MS in Electrical Engineering with an emphasis in MEMS Microelectronics and Biomedical. Dr. Markus spent 11 years with Raytheon and holds 8 US patents and has 9 other US Patents Pending. He has been involved in research for several of the world's leading technological institutions, including the Office of Naval Research in Arlington, Virginia, NASA Jet Propulsion Laboratory in Pasadena, CA and he has been published 15 times for various technical conferences. He was a principal investigator on SBIR DARPA Phase I and Phase II, and "Ultraflexible Substrate" for Macroelectronics Program by Dr. Robert Reuss at DARPA. He has been involved in the engineering and the development on seven surgical devices, including devices for Cataract surgery, Intra-Ocular Lens Delivery, Arthroscopy, Endodontic Endoscope, Micro Endoscope and Neural Electrodes. Additionally he was instrumental on developing three medical laboratory devices, including for In-Vitro Fertilization, PCR instrumentation and drug discovery. Finally, Dr. Markus is fluent in English, Chinese-Madarin, Taiwanese-FuJian and Indonesian languages.
$$$$$ EPGL $$$$$
$EPGL
#MEMS
MD+DI Article-> Nice article on EPGL from a leading industry source.
Will EPGL's TopSpin Serve Up the Next Generation of Medical Devices?
A former DARPA scientist and a device startup want to change medical devices forever using bioMEMS
A phone call with EPGL Medical Science is not unlike a game of Texas hold 'em, you don't know exactly what the guys across the table are holding, but you definitely know you should at least be paying attention. MD+DI profiled EPGL last month when the company announced it would be among the first medical device companies to implement Google Glass technology. But company president and CEO Michael Hayes was more excited about something else going on at EPGL – a bioMEMS platform, codenamed TopSpin, that EPGL says will usher in nothing short of a paradigm shift for medical devices and the doctors and patients that use them. The goal is to do for medical devices what Steve Jobs did for phones.
The ace in the hole is Dr. David T. Markus, the company's VP of bioMEMS development. Markus comes to the company with an extensive background in MEMS, microelectronics, and biomedical engineering. He was also a principal investigator at DARPA, where the forefront of MEMS research has been conducted for years. “They brought together the best scientists in America, essentially doing research that is so advanced, it has little practical use, but not in all cases” Markus laughs. “As a result of being part of those programs and others, some new advanced technology was developed and I just so happened to be involved in the development of some of those technologies. As a result I was able to know how to replicate them for practical use in the medical field.”
Dr. David Markus wants to serve up the world's most advanced medical devices
Markus, who is fluent in seven languages, speaks with an ease that belies just how large of an impact he's attempting to have on the medical device industry. And if Hayes' boast that EPGL is “Three to five years ahead of any device company in this field because of David Markus,” is true, perhaps he should. He and Hayes met as friends on the tennis court and later bonded when Hayes began speaking with him about ideas for new and improved medical devices. “I had all of these ideas and hadn't realized I was contemplating MEMS ideas,” Hayes says. “David has given me quite an education on what the possibilities are with MEMS. Based on that I've made a decision that EPGL is going to be a company focused largely on advanced MEMS devices.”
MEMS technology has already impacted a variety of fields from robotics, to personal fitness, and even digital movie projection. Markus and the team at EPGL figure it is medtech's turn. “The reason why we're very confident is because this isn't dreamland stuff, this is technology that exists right now,” Hayes says. “Everything David is working on is technology that he knows how to implement.”
So what is TopSpin exactly? Or, more accurately, what does it hope to become? Imagine all of the devices doctors now use in the hospital and clinical setting for a wide variety of procedures. Some of these devices and machines are large and require designated rooms in the clinic or hospital for use. Now imagine many of those devices sharing the same core platform with advanced MEMS technology, making them much smaller, less invasive and more effective and you have the beginnings of what TopSpin promises. While Markus and his team are sworn to secrecy for full details, he does promise “Topspin will be small and noninvasive. It will be packed with all necessary smart systems. It can achieve 1 micron in movement. And it is an intelligent microsystem with advanced technology that no Fortune 500 company owns.”
A sample of bioMEMS technology for drug delivery previously developled by Dr.Markus
Markus wants clinicians to feel the same impact with TopSpin that consumers did with the touchscreen not too long ago. “It was shocking when the iPhone finally came to market. People said, 'Wow I didn't know a touchscreen could be this dynamic' “ Markus says. “ I'm sure you remember before the iPhone that the touchscreen experience was only as good as a PDA with stylus. But look at something like Gorilla Glass. It was developed by Corning in 1960 but was put on a shelf. Nobody knew it existed until Apple started using it in the iPhone.” While he remains close-lipped about much of his DARPA background Markus, very modestly, states that “You'd be amazed how much technology is out there and is available in the world.”
Hayes likes to extend the iPhone analogy when talking about TopSpin. Just as the iPhone is more than a phone and functions as a platform for application development (ala the AliveCor heart monitor), so too will TopSpin be a platform for medical device applications. The key distinction is that EPGL doesn't want to create Star Trek-style TriCorder. “We're not saying you'll hold one single device in your hand and it'll do everything,” Hayes says. “ We've developed a platform by which many different MEMS devices can be spawned, but it's all based on two or three components to the main device. But literally dozens and dozens of new devices can result from this one single device. It'll result in several unique patented devices.” As of late Markus and his team are already boasting 10, as yet to be revealed, pain management devices that have been created with the platform. Hayes predicts that anywhere up to five of these devices should be in the prototype phase and undergoing FDA 510(k) applications by fourth quarter 2013.
“The gist of it is is that we're taking bioMEMS technology, utilizing nature and the senses we have as living creatures such as touch, taste, sight, sound, balance, and giving these senses to devices. It's the ability for devices to almost become superhuman,” Hayes says.
“Take a doctor who would never consider doing a certain procedure now because they don't have the facilities or they would normally have to perform the procedure in a hospital or O.R. setting. What we're offering is several devices that will give physicians who don't have the current ability to do certain procedures the ability to do these procedures in a clinical setting in a compact and effective way,” Hayes continues.
If EPGL's ambitions ring true one won't be able to deny the inherent cool factor of the TopSpin. But Markus is quick to emphasize that this is not invention or innovation for the sake of doing so. There's a real goal in helping doctors in speeding up patient recovery and, ultimately, in reducing medical costs. “The device will be produced based on doctors' feedback when treating patients,” he says. “It's not based on any engineer notions of what's good for the doctor. We asked doctors what they needed.”
A paradigm shift? Game changer? Both Hayes and Markus acknowledge how lofty their words must sound, especially without a finished device yet revealed to the public. But Hayes carries himself like a player who knows he has a winning hand, he just needs to wait his turn. “I realize the Fortune 500 companies like Medtronic or St. Jude will look at us and scoff like we're another newcomer trying to thump their chest,” Hayes says. “And to some extent they're right because we're a pittance compared to them currently financially. But we have technology that we know they would love to have and that's what makes us something meaningful and something to recon with in the future.”
Confidence certainly, but as any experienced player will tell you only time will tell whether EPGL is holding the winning cards or have merely mastered the art of the bluff. Still, one gets the sense that Hayes has no trouble looking you in the eye when he says, “We're trying to usher in the era of the smart medical device- smarter medical devices... the smartest medical devices.”
-Chris Wiltz, Associate Editor, MD+DI
$EPGL
#MEMS
#DAVIDMARKUS
New Devices and Intellectual Property Under EPGL Ownership
1.A new advanced ablation device for nerve pain treatment in the back.
2. A new advanced ablation device for nerve treatment of Facial Glabballar Frowning.
3. A new advanced device for elimination of facial wrinkles.
4. A new advanced Epidural device.
5. A new advanced power source for TopSpin medical devices.
6. A new and promising device for treatment of Retinitis Pigmentosa
7. A new and promising device for treatment of Macular Degeneration
8. A new and promising treatment for Hearing Loss
9. A new more accurate treatment for trigger points in the muscles (MPTT)
10. A new advanced device for treatment of prostate tumors.
11. A new advanced endoscopic device.
12. A new advanced device for delivery of micron sized drug payloads.
13. A new advanced device for delivery of micro mechanical devices into the body.
14. A new advanced device for biopsy.
15. A new advanced device for stem cell treatment delivery.
16. A new advanced contact lens device.
$EPGL
#MEMS
#DAVIDMARKUS
Reposting information for the newbies to EPGL, I also suggest they look at the stickies above, a lot of NEW people looking at EPGL, another few days we will have much more new information to go though and digest when filings and or news hit
Over the last few days I have had more people asking me about EPGL through many sources,(NOT JUST HERE), then I probably have over the last 3 months combined, EPGL is hitting many new radars...
I direct them to the DD provided and encourage them to follow EPGL on twitter as well as check out EPGL website.
Recent EPGL Twitter Updates--> 6/19,7/17,7/18,7/23, BELOW
EPGL Twitter Update 6/19/2014 ->
EPGL is leading the advance MEMS technology design and product development for one of the largest companies in its field. A NYSE
The relationship has expanded under phase two and involves co -ownership of product technologies under development. All EPGL technologies are involved. The technology and products will be manufactured by the NYSE company branded under its name and distributed worldwide by that Company and others affiliated. EPGL's role is that of research, design, development and ownership of the various technology applications.
We are developing an "open source" platform with this company to enable many other organizations and entities to create new products with a new platform. EPGL shareholders should realize that this situation is very real and developing. We are getting very much closer to the time we can reveal all. This will happen no later than August 29, 2014.
EPGL is unlike any other OTC Pink Sheet company at this time. Shareholders are right to be excited about our future. By the way, EPGL and our partners could make an announcement sooner that August 29, 2014.
From EPGL management and team, have a wonderful day.
EPGL Twitter Update 7/17/2014
Google took glucose lens as far as they could. Now the "X" man is an ex-man. Enter Novartis to try to figure it out. But Novartis reached out to EPGL not long ago. So whose technology will dominate coming smart lens revolution?
EPGL is leading giants and focused on new smart lens technologies which will enable mass marketing in both health and consumer electronics well into the future.
Many companies and institutions stand to be enabled by our work. EPGL is working with the best in the business and more is to come by August 29, 2014. EPGL shareholders should be excited at the prospects. Have a wonderful weekend from EPGL team.
TWITTER UPDATE 7/18/2014
It can now be revealed that both Novartis and Google reached out to our development team members in recent weeks and months.
This fact should be a clue to the gravity and know-how of our team in both BioMEMS and manufacturing of smart contact lenses.
We intend to set the industry's standard with our enabling technology. Who are we teamed up with? Who will ultimately include EPGL originated technology within their coming smart lenses? August 29th or before, we intend to go into more details as we've previously announced.
TWITTER UPDATES 7/23/2014
Here's an example of the caliber of suitors. Who did we choose to team our technology with? 1/2
The best in the business. Find out soon... 2/2
Read More: http://investorshangout.com/post/view?id=1733...z3BNTCc4vl
Follow EPGL on twitter @EPGLMed
https://twitter.com/EPGLMed
EPGL Weekly Chart ->Major accumulation
EPGL Daily Chart ->
Here is my last response on this issue, because this is what matters.
Who has the sole power to manage the EPGL shares for AJW? Who is the only organization that can buy or sell EPGL shares? By the way, Mr. Hayes has first right of refusal on any sell.
EOM
$$$$$ EPGL $$$$$$
If you're appointed as power of attorney for a piece of property essentially you own it.
